Dr. Miguel Hernández-Bronchud
Specialist in gastrointestinal cancer, pancreatic cancer, colon cancer, gynaecological cancer, central nervous system cancer, skin cancer, lung cancer and sarcomas.
Chemotherapy, hormone therapy, targeted therapies and immunotherapy.
Joined GCCC 360 Centre of Oncological Excellence in 2018, after extensive national and international professional clinical, research and teaching experience.
Medical Oncologist at GCCC 360 Centre of Oncological Excellence since 2018
Years of experience: Since 1990.
- Diploma in Hospital Management and Health Economics at ESADE, Barcelona. 1997.
- Medical Oncology Specialist. 1990.
- Doctor of Medicine, University of Oxford. 1990.
- Specialist in Hematology. 1989.
- Internal Medicine specialist. 1986.
- Bachelor of Medicine and Surgery, University of Oxford. 1983.
- Master in Molecular Biology, University of Cambridge. 1980.
Previous workplaces and positions
- Head of Service at Nuevo Hospital Mollet. 2014-2016
- Head of Cancer Genetic Counselling Program of the Collaboration Program between Family Medicine and Hospital (in development phases) and Rare Tumours Clinic in the new Granollers Oncology Service.
- Coordinator of Tumour Committees and Secretary/President at Hospital General de Granollers and Hospital de Mollet. Breast Cancer, Digestive Cancers, Urological Cancers, and Lung Cancer. 1996-2016
- Head of Oncology at Hospital General de Granollers for 15 years and director of oncology at Vallès Oriental and at Granollers, Mollet and Sant Celoni hospitals. 1996-2011
- Assistant Physician and later Head of Section in the Departments of Medical Oncology and Hematology at Hospital de Sant Pau in Barcelona. 1991-1996
- PI of AMGEN’s first phase I/II clinical study (1986/89) on recombinant human G-CSF (Filgrastim). Published in 1987 in British J of Cancer. This immediately allowed a confirmatory phase III study also in small cell lung cancer with a clear reduction in post-chemotherapy febrile neutropenia and allowed FDA approval of these therapeutic growth factors.
- Member of the Central Protocol Review Committee of the EORTC (European Organization for Research and Treatment of Cancer). Brussels. 1993-1998.
- More than 100 scientific articles and more than twenty books or chapters focusing primarily on molecular oncology, rare cancers, gene therapy, pharmacokinetics, general medicine, molecular genetics, new drug development, and cell and tissue kinetics.
- Editorial board of several medical journals, including Annals of Oncology (founding member), British Medical Journal, The Lancet, British Journal of Cancer.
- ASCO, ESMO, SEOM, AAAS
- Professor at the European School of Oncology. Milan and Barcelona. 1990-2005.
- ESO Ibarica with Prof. J. Estape 1997-2005.
- Doctorate Courses at Universidad de Salamanca, Universidad de Barcelona (UB) and Universidad Autónoma de Barcelona (UAB).
Scientific societies / Committees
- Associate No.: COMB 23515.
- American Society of Hematology (ASH).
- Sociedad Española de Oncología Médica (SEOM).
- American Society of Clinical Oncology (ASCO).
- Visiting Professor. Duke University, North Carolina. USA.
Awards and honours
- ESMO Young Investigator Award. Lugano. 1988.